Navigation Links
Antibodies in Medical Technology

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ: DYAX ) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

Believed by experts to be important for cervical cancer prevention GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an extended follow-up study show that GlaxoSmithKline (NYSE: GSK ) cervical cancer candidate vaccine, CERVARIX(R) generates sustained high levels of neutralizing...

Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma

BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented at the Annual Meeting of the American Association for Cancer Research (A...

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies

BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of the American Association for Cancer Rese...

Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy

- Results of first reported clinical trial of any antibody to TRAIL receptor 2 in combination with chemotherapy, presented at AACR-NCI-EORTC International Conference - - Preclinical study demonstrating synergy of TRAIL receptor antibodies with chemotherapy highlighted ...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic an...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System - - Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic C...

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models- SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (...

Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment

WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S. affiliate of Bayer Schering Pharma AG, Germany, announced today the results of a retrospective study demonstrating that the presence of neutralizing antibodies (NAbs) that can develop in response to Betaseron(R) (interferon beta-1b) ...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

- Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model - - Peregrine's Antibodies that Selectively Inhibit VEGF Receptor 2 Could Potentially Have Advantages over Non-Selective Approaches - - These Results Along wit...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study of HGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (map...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ -- Mymetics Corporation announced today analysis of results demonstrating that the Company's HIV vaccine elicited neutralizing IgA mucosal antibodies in a non-human primate model. Mucosal IgA antibodies are considered as a possible first line...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its T...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's Genetic Research - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. today reported results from preclinical research demonstrating that antibodies directed to a potential new target, angiopoietin-l...

Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies. In a chapter of the text th...

Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies

The Epstein Barr virus (EBV), which causes infectious mononucleosis (IM), is one of the most common human viruses. EBV occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95 percent of adults between 35 and 40 years of age have b...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...an important gene for rat antibody production. Inactivation of rat IgM expression is the first step in generating rats that exclusively express human antibodies encoded by transgenic human immunoglobulin genes. "Creating a knockout rat was the biggest challenge OMT faced," said Dr. Roland Buelow, CEO of OMT a...

Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs

...as achieved several important milestones in advancing its pipeline of novel antibodies since being acquired by Lilly less than a year ago. One of those molecules... Chairman, President and CEO John Lechleiter, Ph.D., "Having six monoclonal antibodies contributed by ImClone to the Lilly oncology portfolio is a great step towa...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

...364 is less expensive to produce than biologics and can be given orally. Moreover, because it is not a protein, CPSI-2364 is not expected to generate antibodies that could neutralize its activity and result in loss of efficacy over time." CPSI-2364 is a chemically-modified form of the synthetic guany...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

...toimmune disorder that affects more than 1.5 million Americans, primarily women in their childbearing years. In lupus, the body's immune system forms antibodies that can attack virtually any healthy organ or tissue, from the kidneys to the brain, heart, lungs, skin, joints and blood. No new treatments for lup...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...t infection. In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Preclinical and cli...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... About Cervarix (R) Cervarix (R) was specifically designed with a novel adjuvant, AS04, to deliver high and sustained levels of antibodies aimed at providing long-term protection against HPV 16 and 18, the most common cervical cancer-causing HPV types. It has been shown to be generally we...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... The most commonly reported ISR was erythema. No serious or severe ISRs were reported, and none led to the discontinuation of patients in the study. antibodies to SIMPONI were detected in 4 percent of golimumab-treated patients (50 mg and 100 mg). The GO-AFTER study was supported by Centocor Ortho Biotec...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...armaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto...armaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto...s. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody pl...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...armaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto...armaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto...s. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody pl...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... . About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and he...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

...ase. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a statistically significant correlation between antibodies to the flagellin CBir1 and HLA haplotypes DQ2.5 and DQ8 in a study of 5,406 patients at risk for celiac disease who are EMA positive. Blood and serum ...

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

... a battery of clinical data including ELISA antibody titers, donor-specific antibodies and the ImmuKnow(R) assay to wean tacrolimus whenever possible. Patients we... a series of clinical tests including ELISA antibody titers, donor-specific antibodies and the ImmuKnow assay beginning 6 months posttransplant and at 2-6 months ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...20 molecules on their surface. B-cells normally protect the body from invading pathogens by developing into plasma cells, which make antibodies. These antibodies directly inactivate pathogens or attach to pathogens to prepare them for destruction by other white blood cells. About Ofatumumab Ofatumumab ...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

...ard cardiac catheterization laboratory via a small incision in the upper leg. Of the twelve patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. The data are consistent with safety established for other rAAV vectors, which has been...

New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer

...lves triggering the body's immune system to attack cancer cells. Monoclonal antibodies are molecules customized to target particular cancers, while cytokines are ...form of neuroblastoma," said Maris. Maris added that the supply of the antibodies and cytokines used in the trial was limited, and that pediatric oncologists...

DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms

...istered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, ...

Novel Vaccine Approach Offers Hope in Fight Against HIV

... away from realization. Most attempts at developing an HIV vaccine have used substances aimed at stimulating the body's immune system to produce antibodies or killer cells that would eliminate the virus before or after it infected cells in the body. However, clinical trials have been disappointing. HIV va...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

...ing. About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and he...

Doctors Urge Precaution to Shield Against Swine Flu

...efense called "acquired immunity" will also be challenged by the new mutant strain of swine flu. It is so radically different from prior strains that antibodies produced by previous flu illnesses, and stored in the immune system's memory, will be ineffective. Therefore, preventing infection and immune respons...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...armaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto...ical data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) (panitumuma...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

...ficant Anti-Tumor Potential of Fully Human Anti-PS antibodies and Expand the Company's PS-Targeting Platform- ...ge biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infe... its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a pr...
Other Tags
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
(Date:11/5/2014)... Kelly Redmond has dedicated his career to understanding ... a general audience. , As deputy director and ... at Nevada,s Desert Research Institute, Redmond has more ... application and dissemination of climate data to the ... Meeting in San Francisco on December 15-19, 2014 ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... 27, 2014 In order to enable people ... Fla., designed an easy way to avoid touching a toilet ... then created a prototype of the patent-pending Toilet Tamer, a ... toilet seat and/or lid in a more sanitary manner. It ... of germs. Overall, it promotes good hygiene and peace of ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... individuals who were allegedly injured by the medication are ... a federal litigation is looking ahead to a status ... According to a Scheduling Order issued earlier this year, ... on December 16th at 10:00 a.m. Items likely to ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
Other Contents